Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/resource/nanopub/NP1276388.RA_OpDtAmA1XPypCv8w_pqHrzsB4lz8YndKNsZvBpyfL8130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP1276388.RA_OpDtAmA1XPypCv8w_pqHrzsB4lz8YndKNsZvBpyfL8130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP1276388.RA_OpDtAmA1XPypCv8w_pqHrzsB4lz8YndKNsZvBpyfL8130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP1276388.RA_OpDtAmA1XPypCv8w_pqHrzsB4lz8YndKNsZvBpyfL8130_provenance.
- NP1276388.RA_OpDtAmA1XPypCv8w_pqHrzsB4lz8YndKNsZvBpyfL8130_assertion description "[Upregulation of HER3 has been found to be a major mechanism underlying drug resistance to EGFR and HER2 tyrosine kinase inhibitors and to endocrine therapy in the treatment of breast cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1276388.RA_OpDtAmA1XPypCv8w_pqHrzsB4lz8YndKNsZvBpyfL8130_provenance.
- NP1276388.RA_OpDtAmA1XPypCv8w_pqHrzsB4lz8YndKNsZvBpyfL8130_assertion evidence source_evidence_literature NP1276388.RA_OpDtAmA1XPypCv8w_pqHrzsB4lz8YndKNsZvBpyfL8130_provenance.
- NP1276388.RA_OpDtAmA1XPypCv8w_pqHrzsB4lz8YndKNsZvBpyfL8130_assertion SIO_000772 25849870 NP1276388.RA_OpDtAmA1XPypCv8w_pqHrzsB4lz8YndKNsZvBpyfL8130_provenance.
- NP1276388.RA_OpDtAmA1XPypCv8w_pqHrzsB4lz8YndKNsZvBpyfL8130_assertion wasDerivedFrom befree-2016 NP1276388.RA_OpDtAmA1XPypCv8w_pqHrzsB4lz8YndKNsZvBpyfL8130_provenance.
- NP1276388.RA_OpDtAmA1XPypCv8w_pqHrzsB4lz8YndKNsZvBpyfL8130_assertion wasGeneratedBy ECO_0000203 NP1276388.RA_OpDtAmA1XPypCv8w_pqHrzsB4lz8YndKNsZvBpyfL8130_provenance.
- befree-2016 importedOn "2016-02-19" NP1276388.RA_OpDtAmA1XPypCv8w_pqHrzsB4lz8YndKNsZvBpyfL8130_provenance.